RBT Biotech Company (BioTechnology Developments) of the Human Stem Cell Institute group (HSCI, MOEX: ISKJ) opened a private offering on the Rounds investment platform.
RBT plans to raise RUB 160 million by private subscription. The funds will be used to expand the portfolio of vaccines developed by the company and to complete clinical trials of the influenza vaccine.
Applications from investors on the Rounds platform are accepted starting from RUB 1 million.
The underwriter of the offering is also the Alfa Investments service. Its clients can invest amounts from RUB 10 thousand in RBT.
RBT is a resident of Skolkovo and Medtech Moscow, the Moscow Center for Innovative Technologies in Healthcare Technopark. Together with HSCI, RBT is developing a platform for the development of candidate antiviral vaccines based on surface recombinant proteins and spherical adjuvant particles. Previously, this platform was used to develop coronavirus vaccine Betuvax-Cov-2 and influenza vaccine TetraFluBET, as well as a pentavalent combination vaccine against influenza and coronavirus developed jointly with the Nacimbio pharmaceutical holding. RBT’s technology platform is aimed at making vaccines less reactogenic and minimizing their side effects, while maintaining the “protective” properties of vaccines, such as immunogenicity, at a high level. The company’s pipeline also includes a human papillomavirus vaccine.
For the investment procedure, please visit: https://rbiotech.ru/invest-rbt